Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Xintela ABFRA:1XT 8 Receivables Turnover is 1.95 as of Mar. 2026. GuruFocus rates FRA:1XT with a GF Score™ of 8/100. The stock has 2 warning signs investors should review. Among 841 Biotechnology companies, Xintela AB ranks better than 73.72% on this metric.
The Receivables Turnover ratio measures the number of times a company collects its average accounts receivable balance. It is calculated as Revenue divided by average Accounts Receivable. An efficient company has a higher accounts receivable turnover ratio while an inefficient company has a lower ratio. Xintela AB's Revenue for the
three
months ended in Mar. 2026 was €0.04 Mil. Xintela AB's average Accounts Receivable for the
three
months ended in Mar. 2026 was €0.02 Mil.
Hence, Xintela AB's Receivables Turnover for the
three
months ended in Mar. 2026 was 1.95.
Xintela AB (FRA:1XT) Receivables Turnover Explanation
An efficient company has a higher accounts receivable turnover ratio while an inefficient company has a lower ratio. This metric is commonly used to compare companies within the same industry to check whether they are on par with their competitors.
Xintela AB Receivables Turnover Related Terms
Xintela AB Receivables Turnover Historical Data
* Premium members only.
The historical data trend for Xintela AB's Receivables Turnover can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
FRA:1XT vs VRTX, REGN, ALNY: Receivables Turnover Comparison
For the Biotechnology subindustry, Xintela AB's Receivables Turnover, along with its competitors' market caps and Receivables Turnover data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Xintela AB Receivables Turnover vs Biotechnology Industry
For the Biotechnology industry and Healthcare sector, Xintela AB's Receivables Turnover distribution charts can be found below:
* The bar in red indicates where Xintela AB's Receivables Turnover falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Xintela AB (FRA:1XT) has a Receivables Turnover of 1.95 as of Mar. 2026. The accounts receivables turnover ratio measures the number of times a company collects its average accounts receivable balance. It is calculated as Revenue divided by Average Accounts Receivable. View historical data on Xintela AB and its competitors. According to the industry distribution chart, Xintela AB ranks #221 out of 841 companies in the Biotechnology industry, placing it in the top 26.3%.
Is Xintela AB's Receivables Turnover too high?
Xintela AB's current Receivables Turnover is 1.95. The Biotechnology industry median Receivables Turnover is 5.29. Xintela AB's value of 1.95 is 63.1% below this industry median. Based on the distribution chart, Xintela AB ranks #221 out of 841 companies in the Biotechnology industry, which is above the industry midpoint. Overall, Xintela AB has a GF Score™ of 8/100, reflecting its overall financial health beyond just this single metric.
How does Xintela AB's Receivables Turnover compare to VRTX and REGN?
According to the Biotechnology industry distribution chart, Xintela AB ranks #221 out of 841 companies for Receivables Turnover. This puts Xintela AB in the upper half of its industry. The industry median Receivables Turnover is 5.29. Xintela AB's value of 1.95 is 63.1% below this benchmark. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Receivables Turnover for a Biotechnology company?
The median Receivables Turnover among Biotechnology companies is 5.29, based on 841 companies in the industry. Companies in the top quartile (top 25%) have a Receivables Turnover significantly above this median, while those in the bottom quartile fall well below. However, Receivables Turnover should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Xintela AB's current Receivables Turnover of 1.95 is 63.1% below the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Receivables Turnover mean?
A high Receivables Turnover can signal that a stock is expensive relative to its fundamentals. The accounts receivables turnover ratio measures the number of times a company collects its average accounts receivable balance. It is calculated as Revenue divided by Average Accounts Receivable. View historical data on Xintela AB and its competitors. For the Biotechnology industry, the median Receivables Turnover is 5.29 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Xintela AB's current Receivables Turnover is 1.95. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Xintela AB stock overvalued right now?
Xintela AB (FRA:1XT) has a current Receivables Turnover of 1.95. The current Receivables Turnover is 1.95 and 63.1% below the Biotechnology industry median of 5.29. Xintela AB's overall GF Score™ is 8/100 with 2 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Receivables Turnover calculated?
Receivables Turnover is calculated from a company's financial statements. For Xintela AB (FRA:1XT), the current Receivables Turnover is 1.95 as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Xintela AB is a clinical-stage biopharmaceutical company that develops cutting-edge medical products in stem cell therapy and targeted cancer therapy. Its wholly owned subsidiary, Targinta AB, develops First-in-Class therapeutic antibodies targeting integrin ?10?1. TARG9, an antibody-drug conjugate (ADC), and TARG10, a function-blocking antibody, are in preclinical development for the treatment of aggressive, difficult-to-treat cancers, including triple-negative breast cancer and brain tumor glioblastoma. Xintela has two clinical studies ongoing with the stem cell product XSTEM and EQSTEM.
8GF Score
Get the complete analysis for FRA:1XT
Receivables Turnover is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
FRA:1XT has been successfully added to your 
